Compare Tango Therapeutics Inc. (TNGX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs GeneDx Holdings Corp — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| TNGX | WGS | |
|---|---|---|
Market Cap | $3.75B | $1.94B |
Volume | 9,619,106 | 524,385 |
Sector | Health | Health |
52-Week High | $32.90 | $167.51 |
52-Week Low | $7.50 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $2.77B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
